Skip to content
Technology Opportunities & Ventures
While focus is on header menu items,
press the down arrow to open sub-menu.

For Innovators

Getting your innovations out into the world and to the people that need them.

In This Section

‹ Home › For Industry › Innovation Spotlights › Article

For Industry

Small Molecule Antagonist of the RAGE-DIAPH1 Signaling Axis for Diabetic Kidney Disease (DKD) Treatment

Treating diabetes-associated diseases with a small molecule inhibitor that blocks the RAGE protein's ability to pass on inflammatory signals that injure the heart and kidneys.

Ann Marie Schmidt, PhD, discusses the capabilities of the small molecule inhibitor.

A research team led by Ann Marie Schmidt, MD, at NYU Langone Health has developed a new way to treat diabetes-associated diseases with a small molecule inhibitor that blocks the RAGE protein’s ability to pass on inflammatory signals that injure the heart and kidneys.

This compound displays superior characteristics to the 1st generation compound RAGE229, which showed strong POC activity in a prior study published in Science Translational Medicine.

Read More